A. They stimulate activated cytotoxic T-cells to proliferate B. They inhibit the checkpoint signals, pushing activated cytotoxic T-cells into exhaustion C. They augment the cytotoxic T-cells' ability to respond to cancer-associated antigens D. They enhance cytotoxic T-cell secretion of lethal cytokines like granzyme and perforin E. Unsure

A. The underlying cause is different, and the management is different B. They both cause the gut to become denuded and treatment is the same C. One is caused by increased motility while the other is caused by gut denudation D. Immune mediated diarrhea is managed with octreotide, while chemotherapy induced diarrhea is managed with loperamide E. Unsure

A. Most toxicity seen with cytotoxic chemotherapy occurs after several doses B. Most toxicity seen with immunotherapy occurs after the first dose C. Toxicity with immunotherapy is predictable based on dose and time of administration D. The median time to toxicity onset with immunotherapy is delayed (cycle 4 or beyond) E. Unsure

A. Treatment should not be reinstituted for this degree of toxicity B. Treatment does not need to be interrupted for this degree of toxicity C. Treatment can be reinstituted at the same dose once toxicity improves D. Treatment can be reinstituted at a lower dose once toxicity improves E. Unsure

A. The likelihood of the toxicity recurring is very high B. A toxicity-induced therapy delay is associated with diminished efficacy C. The risk of recurring toxicity is very low after successful management D. Interrupting therapy does not impair the benefit with restarting treatment E. Unsure

A. A pocket card they are encouraged to keep with them B. A bracelet informing others they are on immunotherapy (similar to an allergy bracelet) C. A memory card (e.g. a sim card) with their medical record and medications D. There is no tool or recommendation in the guideline E. Unsure

A. Assigning 1 dedicated person to triage all the immune related phone calls B. Send all patients home with a prescription for low dose prednisone C. Educate staff, including non-clinical staff about immune related toxicity D. Create a process that can see patients within three days E. Unsure

A. They unanimously felt like the therapies were very similar due to the fatigue B. They unanimously felt the chemotherapy was much more toxic C. Two of the three felt that immunotherapy was less toxic than chemotherapy D. Two of the three felt the chemotherapy was easier to handle than immunotherapy E. Unsure

A. The travel to and from the cancer center B. The financial burden it placed on them C. The inability to reach the oncology team when needed D. They didn't identify any logistical barriers E. Unsure